ACADIA Pharmaceuticals Inc.
ACAD
$21.72
-$0.08-0.37%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 9.93% | 11.87% | 12.69% | 14.41% | 22.42% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.93% | 11.87% | 12.69% | 14.41% | 22.42% |
| Cost of Revenue | 4.91% | 8.49% | 23.67% | -6.46% | -0.98% |
| Gross Profit | 13.32% | 14.14% | 6.14% | 34.19% | 45.61% |
| SG&A Expenses | 17.11% | 12.38% | 11.40% | 20.45% | 22.62% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.72% | 10.67% | 16.61% | 7.02% | 10.94% |
| Operating Income | -8.44% | 24.36% | -15.88% | 295.77% | 2,027.13% |
| Income Before Tax | -56.54% | -46.18% | 100.21% | 485.61% | 1,676.93% |
| Income Tax Expenses | -824.36% | -897.17% | 52.63% | 201.21% | 116.49% |
| Earnings from Continuing Operations | 64.12% | 72.66% | 103.24% | 626.84% | 13,484.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 64.12% | 72.66% | 103.24% | 626.84% | 13,484.97% |
| EBIT | -8.44% | 24.36% | -15.88% | 295.77% | 2,027.13% |
| EBITDA | -8.81% | 16.38% | -12.91% | 203.34% | 1,575.15% |
| EPS Basic | 61.40% | 69.76% | 100.76% | 627.33% | 11,962.07% |
| Normalized Basic EPS | -4.22% | 22.59% | -4.78% | 197.32% | 1,110.05% |
| EPS Diluted | 60.89% | 68.71% | 100.61% | 660.79% | 7,291.58% |
| Normalized Diluted EPS | -4.78% | 22.09% | -4.85% | 202.07% | 1,197.95% |
| Average Basic Shares Outstanding | 1.75% | 1.50% | 1.34% | 1.18% | 1.15% |
| Average Diluted Shares Outstanding | 2.50% | 1.91% | 1.23% | 0.86% | 0.65% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |